Widely used:Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹3,861 Cr
P/E Ratio
47.1
P/B Ratio
6.51
Industry P/E
37.33
Debt to Equity
0.6
ROE
16.17 %
ROCE
15.42 %
Div. Yield
0.03 %
Book Value
59.18
EPS
8.18
CFO
₹209.64 Cr
EBITDA
₹706.26 Cr
Net Profit
₹387.52 Cr
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Gufic Biosciences
| -15.37 | 13.29 | -10.79 | 20.16 | 12.21 | 43.46 | 36.55 |
|
BSE Healthcare
| -5.01 | 1.86 | -0.55 | 24.06 | 20.25 | 23.06 | 9.92 |
|
BSE Small Cap
| -10.13 | 4.11 | -3.92 | 5.91 | 18.96 | 35.49 | 15.85 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Gufic Biosciences
| 44.75 | 39.74 | -4.69 | 96.04 | 93.47 | -35.40 | -25.80 |
|
BSE Small Cap
| 29.04 | 47.52 | -1.80 | 62.77 | 32.11 | -6.85 | -23.41 |
|
BSE Healthcare
| 43.09 | 36.97 | -12.10 | 20.87 | 61.45 | -3.55 | -5.89 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | P/E Ratio | ROE |
|---|---|---|---|---|
| 426.60 | 7,122.13 | 25.96 | 12.5 | |
| 5,219.50 | 8,681.48 | 36.7 | 43.77 | |
| 722.65 | 7,088.86 | 80.29 | 4.01 | |
| 681.40 | 6,346.32 | 23.54 | 12.68 |
No Review & Analysis are available.
Gufic Biosciences Limited manufactures and markets active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services in India, Africa, Asia, Europe, Australia, North America, South America, and internationally. The company... manufactures APIs and bulk drugs, such as antifungals, anesthetics, immuno suppressants, and intermediates for antifungals. It manufactures lyophilized injections, which include antibiotic, antifungal, cardiac, infertility, antiviral, and proton-pump inhibitor segments. In addition, the company offers spark, criti care, criticare life, and ferticare pharmaceutical products; and herbal, aesthaderm, gufic stridden, and personal care products. It supplies its products to hospital chains and medical facilities. Gufic Biosciences Limited was founded in 1970 and is based in Mumbai, India. Read more
Incorporated
1984
Chairman
Jayesh P Choksi
Managing Director
Jayesh P Choksi
Headquarters
Mumbai, Maharashtra
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Gufic Biosciences Ltd stood at ₹ 1,105 Cr as on 31-Dec-24
The share price of Gufic Biosciences Ltd is ₹385.30 (NSE) and ₹384.55 (BSE) as of 24-Apr-2025 15:09 IST. Gufic Biosciences Ltd has given a return of 12.21% in the last 3 years.
Gufic Biosciences Ltd has a market capitalisation of ₹ 3,861 Cr as on 24-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Gufic Biosciences Ltd is 6.51 times as on 24-Apr-2025, a 22% premium to its peers’ median range of 5.35 times.
The P/E ratio of Gufic Biosciences Ltd is 47.10 times as on 24-Apr-2025, a 26% premium to its peers’ median range of 37.33 times.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Gufic Biosciences Ltd and enter the required number of quantities and click on buy to purchase the shares of Gufic Biosciences Ltd.
Gufic Biosciences Limited manufactures and markets active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services in India, Africa, Asia, Europe, Australia, North America, South America, and internationally. The company manufactures APIs and bulk drugs, such as antifungals, anesthetics, immuno suppressants, and intermediates for antifungals. It manufactures lyophilized injections, which include antibiotic, antifungal, cardiac, infertility, antiviral, and proton-pump inhibitor segments. In addition, the company offers spark, criti care, criticare life, and ferticare pharmaceutical products; and herbal, aesthaderm, gufic stridden, and personal care products. It supplies its products to hospital chains and medical facilities. Gufic Biosciences Limited was founded in 1970 and is based in Mumbai, India.
The prominent promoters of Gufic Biosciences Ltd. are
| Name of promoters | Holding percentage |
|---|---|
|
Jayesh Pannalal Choksi |
24.62%
|
|
Zircon Teconica Private Limited |
20.47%
|
|
Gufic Private Limited |
10.16%
|
|
Vipula Jayesh Choksi |
10.01%
|
|
Pranav Jayesh Choksi |
7.25%
|
The chairman of the company is Jayesh P Choksi, and the managing director is Jayesh P Choksi.
There is no promoter pledging in Gufic Biosciences Ltd.
Some of the close peers are:
| Company | Market Cap(₹ Cr) |
|---|---|
|
8,680
|
|
|
7,005
|
|
|
6,570
|
|
|
6,016
|
| Gufic Biosciences Ltd. | Ratios |
|---|---|
|
Return on equity(%)
|
14.81
|
|
Operating margin(%)
|
15.43
|
|
Net Margin(%)
|
10.07
|
|
Dividend yield(%)
|
0.03
|
Yes, TTM profit after tax of Gufic Biosciences Ltd was ₹82 Cr.
₹24.25
(
